SCHEMBL12265149

SCHEMBL12265149

CC(C)(C)OC(=O)N[C@H]1CCCC[C@@H]1C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BTK Q06187 1/20 0.46
GAA P10253 2/20 0.45
EPHX1 P07099 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
HDAC4 P56524 2/20 0.43
HDAC6 Q9UBN7 2/20 0.43
KDM1A O60341 2/20 0.43
CCR1 P32246 1/20 0.42
MAOB P27338 1/20 0.41
CTSK P43235 2/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HDAC1 Q13547 1/20 0.39
PDE4B Q07343 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19773841 0.87 BTK (0.53) BTKGAAEPHX1NFKB1NFKB2
SCHEMBL765253 0.87 BTK (0.53) BTKGAAEPHX1NFKB1NFKB2
SCHEMBL12885089 0.87 BTK (0.53) BTKGAAEPHX1NFKB1NFKB2
SCHEMBL24062392 0.83 BTK (0.57) BTKGAAEPHX1NFKB1NFKB2
SCHEMBL12649367 0.83 BTK (0.57) BTKGAAEPHX1NFKB1NFKB2
SCHEMBL16099696 0.83 BTK (0.57) BTKGAAEPHX1NFKB1NFKB2
SCHEMBL2560495 0.83 BTK (0.58) BTKGAAEPHX1NFKB1NFKB2
SCHEMBL14346489 0.83 BTK (0.58) BTKGAAEPHX1NFKB1NFKB2
SCHEMBL169972 0.83 BTK (0.58) BTKGAAEPHX1NFKB1NFKB2
SCHEMBL2563637 0.83 BTK (0.58) BTKGAAEPHX1NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8557832-B2 Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators MERCK SHARP & DOHME CORP. (US) 2013-10-15 US disclosed
US-20110224198-A1 ARYL METHYL BENZOQUINAZOLININE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK SHARP & DOHME LLC 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224198-A1 ARYL METHYL BENZOQUINAZOLININE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, OPRL1, CHRM2 BTK 1581/4885GAA 3216/4885EPHX1 3320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.